Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia

Our Review Board

Our content is carefully reviewed by experienced professionals to ensure accuracy and relevance.

• Qualified Experts: Each article is assessed by specialists with field-specific knowledge.
• Up-to-date Insights: We incorporate the latest research, trends, and standards.
• Commitment to Quality: Reviewers ensure clarity, correctness, and completeness.

Look for the expert-reviewed label to read content you can trust.